Home Newsfeeds Amazon.com to Invest Over €1B in European Electric Van, Truck Fleet

Amazon.com to Invest Over €1B in European Electric Van, Truck Fleet

-Reuters https://www.reuters.com/business/autos-transportation/amazoncom-invest-over-1-bln-euros-european-electric-van-truck-fleet-2022-10-09/

byCharles Gross

October 9, 2022

1 minute read

-Reuters

https://www.reuters.com/business/autos-transportation/amazoncom-invest-over-1-bln-euros-european-electric-van-truck-fleet-2022-10-09/

Check Out What Whales Are Doing With XOM

By Benzinga Insights

August 25, 1:46 PM

A whale with a lot of money to spend has taken a noticeably bearish stance on Exxon Mobil.…

XOM

News

Alpha Tau Enters Into Long-Term Lease Of Site In New Hampshire For Second U.S. Manufacturing Facility

By Benzinga Newsdesk

October 30, 8:36 AM

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its U.S. subsidiary, Alpha Tau

DRTS

JP Morgan Upgrades MPLX to Overweight, Raises Price Target to $41

By Benzinga Newsdesk

March 14, 5:19 AM

JP Morgan analyst Jeremy Tonet upgrades MPLX (NYSE:MPLX) from Neutral to Overweight and raises the price target from $37 to $41.

MPLX

FDA
News

Erasca Granted FDA Orphan Drug Designation For CNS-Penetrant EGFR Inhibitor ERAS-801 For The Treatment Of Malignant Glioma; ERAS-801 Has Now Received ODD In Addition To FDA Fast Track Designation

By Benzinga Newsdesk

June 22, 4:02 PM

ERAS-801 has now received ODD in addition to FDA Fast Track DesignationInitial THUNDERBBOLT-1 Phase 1 monotherapy data in patients with recurrent GBM expected in H2 2023SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) --

ERAS

Amazon.com to Invest Over €1B in European Electric Van, Truck Fleet

Related Posts

Check Out What Whales Are Doing With XOM

Alpha Tau Enters Into Long-Term Lease Of Site In New Hampshire For Second U.S. Manufacturing Facility

JP Morgan Upgrades MPLX to Overweight, Raises Price Target to $41

Erasca Granted FDA Orphan Drug Designation For CNS-Penetrant EGFR Inhibitor ERAS-801 For The Treatment Of Malignant Glioma; ERAS-801 Has Now Received ODD In Addition To FDA Fast Track Designation